Health Matters: Prescription drug costs a barrier for Black Canadians

A new study in the Canadian Medical Association Journal finds Black Canadians are more likely to skip prescriptions due to cost and have lower prescription drug insurance coverage than white Canadians, highlighting racial disparities in medication access. The article provides no specific percentages or dollar magnitudes; findings could inform insurers, benefits design and health-policy discussions.

Analysis

This disparity is a demand-side shock that will re-route prescription volume toward lower-cost channels and non-traditional care over the next 6–24 months. Even small increases in cost-driven non-adherence (low single-digit percentage points persistently) compress retail pharmacy prescription fills and push patients to generics, private-label substitutes, discount big-box pharmacies, and telehealth triage services—changing where margin accrues in the chain.

Second-order winners are operators with scale in low-price fulfillment and digital-first care (fulfillment cost per script falls materially with volume); losers are retail pharmacies and branded manufacturers that rely on per-script gross margins and sticky private insurance reimbursement. Insurers and provincial payers face political pressure to expand coverage or subsidize fills, which would redistribute cashflows away from discretionary retail margins toward government budgets or PBM/insurer-negotiated rebates.

Key catalysts: provincial pilot programs, federal policy debates or announcement of targeted subsidies (weeks–months), earnings updates showing persistent volume migration (quarterly), and patient assistance program rollouts by manufacturers (near-term reversal potential). Tail risk is a faster-than-expected policy swing to broader pharmacare or aggressive price-regulation: that would rerate branded exposure within 12–36 months.

Consensus underestimates how quickly retail share can shift without formal policy change: private behavior + employer plan gaps can reallocate tens of percent of marginal fills to discount channels within one year. That makes scaled Canadian retail and digital health plays asymmetric — durable volume gains at low per-unit margin but high cashflow stability — while branded pharma exposure in Canada is exposed to policy and substitution risk that is likely underpriced.

Key Decisions for Investors

• Overweight Loblaw Companies Ltd (L.TO) — 12 month. Rationale: captures price-sensitive prescription flow via Shoppers and private-label generics; entry: initiate 1.5–2.0% NAV position; risk/reward: limited downside from grocery moat, upside from pharmacy market share; stop-loss 12% below entry if provincial policy cited as imminent.
• Buy Walmart Inc (WMT) — tactical 6–12 month overweight. Rationale: defensive retail play to capture low-cost prescription and OTC migration; entry: buy on weakness or accumulate in 2 tranches; risk/reward: low volatility, modest upside if volume shift persists; hedge with covered calls if share price rises >15%.
• Buy WELL Health Technologies Corp (WELL.TO) — 6–18 month. Rationale: digital-first primary care and telemedicine to absorb unmet demand from cost-sensitive patients; entry: 1% NAV position with staged buys on quarterly revenue beats; risk/reward: execution risk at integration, but asymmetric upside if telehealth adoption accelerates.
• Pair trade: Long Teva Pharmaceutical (TEVA) / Short Pfizer (PFE) — 6–12 month. Rationale: generics gain share from cost sensitivity while large branded exposure faces price/regulatory tail risk; entry: dollar-neutral pair sized to volatility; risk/reward: TEVA upside if substitution accelerates, PFE downside if pricing pressure/regulatory talk increases; unwind on clear federal pharmacare legislation (policy clarity).